GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Beneish M-Score
中文

Revvity (Revvity) Beneish M-Score : -2.12 (As of Apr. 24, 2024)


View and export this data going back to 1983. Start your Free Trial

What is Revvity Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.12 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Revvity's Beneish M-Score or its related term are showing as below:

RVTY' s Beneish M-Score Range Over the Past 10 Years
Min: -2.68   Med: -2.47   Max: -2.1
Current: -2.12

During the past 13 years, the highest Beneish M-Score of Revvity was -2.10. The lowest was -2.68. And the median was -2.47.


Revvity Beneish M-Score Historical Data

The historical data trend for Revvity's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Beneish M-Score Chart

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.38 -2.10 -2.49 -2.68 -2.12

Revvity Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.68 -2.75 -2.64 -1.89 -2.12

Competitive Comparison of Revvity's Beneish M-Score

For the Diagnostics & Research subindustry, Revvity's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revvity's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Revvity's Beneish M-Score falls into.



Revvity Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Revvity for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2434+0.528 * 1.0733+0.404 * 1.0139+0.892 * 0.8305+0.115 * 0.9873
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.201+4.679 * 0.05123-0.327 * 0.8797
=-2.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $633 Mil.
Revenue was 695.901 + 670.739 + 709.066 + 674.865 = $2,751 Mil.
Gross Profit was 383.478 + 372.516 + 402.331 + 381.366 = $1,540 Mil.
Total Current Assets was $3,001 Mil.
Total Assets was $13,565 Mil.
Property, Plant and Equipment(Net PPE) was $665 Mil.
Depreciation, Depletion and Amortization(DDA) was $432 Mil.
Selling, General, & Admin. Expense(SGA) was $1,020 Mil.
Total Current Liabilities was $1,450 Mil.
Long-Term Debt & Capital Lease Obligation was $3,311 Mil.
Net Income was 78.563 + 9.497 + 35.559 + 569.475 = $693 Mil.
Non Operating Income was -44.533 + -16.092 + -3.255 + -29.213 = $-93 Mil.
Cash Flow from Operations was 196.613 + -33.485 + -135.319 + 63.463 = $91 Mil.
Total Receivables was $613 Mil.
Revenue was 741.214 + 711.803 + 895.642 + 963.163 = $3,312 Mil.
Gross Profit was 436.33 + 407.044 + 551.716 + 594.74 = $1,990 Mil.
Total Current Assets was $3,289 Mil.
Total Assets was $14,130 Mil.
Property, Plant and Equipment(Net PPE) was $671 Mil.
Depreciation, Depletion and Amortization(DDA) was $427 Mil.
Selling, General, & Admin. Expense(SGA) was $1,023 Mil.
Total Current Liabilities was $1,544 Mil.
Long-Term Debt & Capital Lease Obligation was $4,093 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(632.811 / 2750.571) / (612.78 / 3311.822)
=0.230065 / 0.185028
=1.2434

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1989.83 / 3311.822) / (1539.691 / 2750.571)
=0.600826 / 0.559771
=1.0733

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3001.091 + 664.737) / 13564.665) / (1 - (3288.558 + 671.301) / 14129.855)
=0.729752 / 0.719752
=1.0139

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2750.571 / 3311.822
=0.8305

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(427 / (427 + 671.301)) / (431.769 / (431.769 + 664.737))
=0.388782 / 0.393768
=0.9873

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1020.362 / 2750.571) / (1022.953 / 3311.822)
=0.370964 / 0.308879
=1.201

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3310.517 + 1450.463) / 13564.665) / ((4093.315 + 1544.483) / 14129.855)
=0.350984 / 0.398999
=0.8797

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(693.094 - -93.093 - 91.272) / 13564.665
=0.05123

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Revvity has a M-score of -2.12 suggests that the company is unlikely to be a manipulator.


Revvity Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Revvity's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Revvity (Revvity) Business Description

Traded in Other Exchanges
Address
940 Winter Street, Waltham, MA, USA, 02451
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Executives
Anita Gonzales officer: Please See Remarks 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra officer: Please See Remarks 940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg officer: See Remarks 940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121

Revvity (Revvity) Headlines